alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Editorial Note on Part 862
Editorial Note: Nomenclature changes to part 862 appear at 73 FR 35341, June 23, 2008.

§ 862.1470 Lipid (total) test system. ( a ) *Identification.* A lipid (total) test system is a device intended to measure total lipids (fats or fat-like substances) in serum and plasma. Lipid (total) measurements are used in the diagnosis and treatment of various diseases involving lipid metabolism and atherosclerosis.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9.
[52 FR 16122, May 1, 1987, as amended at 53 FR 21449, June 8, 1988; 66 FR 38788, July 25, 2001]
I 

118TH CONGRESS 

2D SESSION H. R. 7800 

To direct the United States Postal Service to designate a single, unique 

ZIP Code for Scotland, Connecticut. 

IN THE HOUSE OF REPRESENTATIVES 

MARCH 22, 2024 

Mr. COURTNEY introduced the following bill; which was referred to the 

Committee on Oversight and Accountability 

A BILL 

To direct the United States Postal Service to designate a 

single, unique ZIP Code for Scotland, Connecticut. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SINGLE, UNIQUE ZIP CODE FOR SCOTLAND, 

4 CONNECTICUT. 

5 Not later than 180 days after the date of enactment 

6 of this Act, the United States Postal Service shall des7 ignate a single, unique ZIP Code, to be numbered 06264, 

8 applicable to the area encompassing solely Scotland, Con9 necticut. 

Æ 


ssavage on LAPJG3WLY3PROD with BILLS
<TABLE> <S> <C>

<ARTICLE> 5
<CIK> 0000814576
<NAME>  PAINEWEBBER R&D PARTNERS II, L.P.
       
<S>                                     <C>
<PERIOD-TYPE>                           3-MOS
<FISCAL-YEAR-END>                                     MAR-31-1998
<PERIOD-END>                                          DEC-31-1998
<CASH>                                                      6,998
<SECURITIES>                                            6,788,002
<RECEIVABLES>                                           1,178,594
<ALLOWANCES>                                                    0
<INVENTORY>                                                     0
<CURRENT-ASSETS>                                        7,986,661
<PP&E>                                                          0
<DEPRECIATION>                                                  0
<TOTAL-ASSETS>                                          7,986,661
<CURRENT-LIABILITIES>                                     206,976
<BONDS>                                                         0
<PREFERRED-MANDATORY>                                           0
<PREFERRED>                                                     0
<COMMON>                                                        0
<OTHER-SE>                                              7,779,685
<TOTAL-LIABILITY-AND-EQUITY>                            7,986,661
<SALES>                                                         0
<TOTAL-REVENUES>                                        1,622,395
<CGS>                                                           0
<TOTAL-COSTS>                                                   0
<OTHER-EXPENSES>                                           47,448
<LOSS-PROVISION>                                                0
<INTEREST-EXPENSE>                                              0
<INCOME-PRETAX>                                         1,574,947
<INCOME-TAX>                                                    0
<INCOME-CONTINUING>                                             0
<DISCONTINUED>                                                  0
<EXTRAORDINARY>                                                 0
<CHANGES>                                                       0
<NET-INCOME>                                            1,574,947
<EPS-PRIMARY>                                                   0
<EPS-DILUTED>                                                   0
        

</TABLE>
Exhibit







March 6, 2017


Steven Fife 
stevefife22@yahoo.com 


Dear Steve,


LifeVantage Corporation (the “Company”), is pleased to offer you a position as Chief Financial Officer reporting directly to our President and Chief Executive Officer. We trust that your knowledge, skills and experience will be among our most valuable assets.


		
	•
	Salary: Annual gross starting salary of $330,000 paid in installments by direct deposit.


		
	•
	Performance Bonuses:  Subject to approval by the Board of Directors each fiscal year and beginning in FY18, participation in the Employee Bonus Plan at the Executive level with a target bonus of 50% of your annual base pay. If your start date is in March 2017, you will also be eligible for the FY17 Q4 personal goal.


		
	•
	Signing Bonus: On your first regular paycheck, you will receive an additional $25,000 as a signing bonus. Should you voluntarily leave your employment with LifeVantage within your first year of employment, you will be responsible to repay this to LifeVantage.


		
	•
	Equity:  Upon approval of the Board of Directors, an equity grant in the amount of 90,000 restricted stock units vesting 30,000 at year one, 30,000 at year two and 30,000 at year three. After the initial new hire grant, participation annually in the executive equity plan beginning in FY18.


		
	•
	Benefits: Executive benefits as described in the attached Key Executive Benefits Agreement.


		
	•
	Moving Expenses: The Company will assist you with relocation expenses:


		
	o
	Reasonable moving costs as outlined in the relocation package with receipts;


		
	o
	Closing and associated realtor costs on your home in Texas and on a new home in Utah;


		
	o
	Temporary living expenses up to six months;


		
	o
	Commutation expenses during the interim- we prefer you use our travel agency to book travel; and


		
	o
	Two house hunting trips with your wife.




To accept this job offer:  Sign and date this job offer letter where indicated below.


If you accept this job offer, your hire date will be no later than April 1, 2017, as we would very much like you to be part of our strategic planning effort and participate in our upcoming April global convention.


Please be aware that this offer of employment is contingent upon your passing a drug screening and background check. LifeVantage is strongly committed to maintaining a drug-free workplace, and providing a safe and productive work environment for you. To maintain this environment, LifeVantage requires all new employees to pass a drug-screening test as a condition of employment, the results of which remain confidential. Upon your acceptance, we will send paperwork for both.


	
		
	Sincerely,




Michelle Oborn
Vice President Human Resources
	Agreed to and accepted this ___ day of March, 2017.






Steven Fife
Exhibit 15.1




Board of
Directors and Partners of


Icahn
Enterprises L.P.





We have
reviewed, in accordance with the standards of the Public Company Accounting
Oversight Board (United States), the unaudited consolidated interim financial
statements of Icahn Enterprises L.P. and Subsidiaries as of June 30, 2009, and
for the three-month and six-month periods ended June 30, 2009 and 2008, as
indicated in our report dated August 5, 2009; because we did not perform an
audit, we expressed no opinion on that information.





We are
aware that our report referred to above, which is included in your Quarterly
Report on Form 10-Q for the quarter ended June 30, 2009 is incorporated by
reference in Registration Statements on Forms S-3 (File No. 333-158705, File No.
333-143930 and File No. 333-126069) and Form S-4 (File No.
333-143929).





We also
are aware that the aforementioned report, pursuant to Rule 436(c) under the
Securities Act of 1933, is not considered a part of the Registration Statement
prepared or certified by an accountant within the meaning of Sections 7 and 11
of that Act.





/s/ GRANT
THORNTON LLP





New York,
New York


August 5,
2009
<TABLE> <S> <C>

<ARTICLE> 5
       
<S>                                      <C>
<PERIOD-TYPE>                                    9-MOS
<FISCAL-YEAR-END>                          DEC-31-1998
<PERIOD-END>                               SEP-30-1998
<CASH>                                           1,579
<SECURITIES>                                         0
<RECEIVABLES>                                3,206,319
<ALLOWANCES>                                   146,000
<INVENTORY>                                  2,606,420
<CURRENT-ASSETS>                             5,780,414
<PP&E>                                       8,914,542
<DEPRECIATION>                               4,295,446
<TOTAL-ASSETS>                              10,802,215
<CURRENT-LIABILITIES>                        5,039,730
<BONDS>                                      2,550,053
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                           417
<OTHER-SE>                                  (4,315,149)
<TOTAL-LIABILITY-AND-EQUITY>                10,802,215
<SALES>                                     13,508,603
<TOTAL-REVENUES>                            13,508,603
<CGS>                                       12,008,674
<TOTAL-COSTS>                               12,008,674
<OTHER-EXPENSES>                             2,080,901
<LOSS-PROVISION>                                45,531
<INTEREST-EXPENSE>                             444,021
<INCOME-PRETAX>                            (2,249,730)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                        (2,249,730)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                               (2,249,730)
<EPS-PRIMARY>                                   (0.05)
<EPS-DILUTED>                                   (0.05)
        

</TABLE>
<TABLE> <S> <C>


<ARTICLE>                     5                    
<MULTIPLIER>                  1,000                 
<CURRENCY>                    U.S. Dollars                 
       
<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>               JUN-30-1997               
<PERIOD-START>                  JUL-01-1996    
<PERIOD-END>                    MAR-31-1997    
<EXCHANGE-RATE>                 1               
<CASH>                                    7              
<SECURITIES>                              0    
<RECEIVABLES>                         2,155    
<ALLOWANCES>                             98    
<INVENTORY>                           9,641    
<CURRENT-ASSETS>                     12,109    
<PP&E>                                9,411    
<DEPRECIATION>                        3,110    
<TOTAL-ASSETS>                       19,785    
<CURRENT-LIABILITIES>                 6,115    
<BONDS>                                   0    
<PREFERRED-MANDATORY>                     0    
<PREFERRED>                               0    
<COMMON>                                  3    
<OTHER-SE>                            6,513    
<TOTAL-LIABILITY-AND-EQUITY>         19,785    
<SALES>                              50,298    
<TOTAL-REVENUES>                     50,298    
<CGS>                                31,782    
<TOTAL-COSTS>                        18,265    
<OTHER-EXPENSES>                          0    
<LOSS-PROVISION>                          0    
<INTEREST-EXPENSE>                      469    
<INCOME-PRETAX>                        (218)    
<INCOME-TAX>                           (132)   
<INCOME-CONTINUING>                     (86)   
<DISCONTINUED>                            0   
<EXTRAORDINARY>                           0    
<CHANGES>                                 0    
<NET-INCOME>                            (86)    
<EPS-PRIMARY>                         (0.03)   
<EPS-DILUTED>                         (0.03)         
        

</TABLE>
1

 
In respect of payments made by Buyer to OCI pursuant to Section 4.1 of the Agreement, Buyer shallbe entitled to an advance payment credit (“Advance Payment Credit”) which shall be calculated asfollows:                       **Aggregate Advance**      **Advance Payment** **Payment Credit for the**      **Credit per kg** **Calendar Year****Calendar Year** **Annual Quantity** **(US$)** **(US$)**2009 [****]kgs [****]/kg  [****] 2010 [****]kgs [****]/kg  [****] 2011 [****]kgs [****]/kg  [****] 2012 [****]kgs [****]/kg  [****] 2013 [****]kgs [****]/kg  [****] 2014 [****]kgs [****]/kg  [****] 2015 [****]kgs [****]/kg  [****]        Total [****]kgs      [****]        3. To the extent there are any inconsistencies or ambiguities between this First Amendment and theOriginal Agreement, the terms of this First Amendment shall supercede those of the OriginalAgreement.4. Except as expressly agreed and amended herein, all of the terms and conditions of theOriginal Agreement shall continue in full force and effect.5. This First Amendment shall be governed by and construed and enforced in accordance with the lawsof the Republic of Korea, without giving effect to the rules respecting its conflicts of lawsprinciples.6. This First Amendment may be executed in one or more counterparts, each of which shall be deemedas an original, but all of which together shall constitute one and the same instrument.
2

 
IN WITNESS WHEREOF, the parties hereto have duly executed and delivered this FirstAmendment as of the day and year first above written.      OCI Company Ltd. Evergreen Solar Inc.       By:   /s/ MinKyu Lim By:  /s/ Richard G. Chleboski  Name: MinKyu Lim  Name: Richard G. Chleboski  Title: Executive Vice President  Title: Vice President 
3
Editorial Note on Part 874
Editorial Note: Nomenclature changes to part 874 appear at 73 FR 35341, June 23, 2008.

§ 874.3375 Battery-powered artificial larynx. ( a ) *Identification.* A battery-powered artificial larynx is an externally applied device intended for use in the absence of the larynx to produce sound. When held against the skin in the area of the voicebox, the device generates mechanical vibrations which resonate in the oral and nasal cavities and can be modulated by the tongue and lips in a normal manner, thereby allowing the production of speech.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 874.9.
[51 FR 40389, Nov. 6, 1986, as amended at 59 FR 63009, Dec. 7, 1994; 66 FR 38800, July 25, 2001]
Presidential Documents

10157 

Federal Register 

Vol. 75, No. 42 

Thursday, March 4, 2010 

Title 3— 

The President 

Notice of February 26, 2010 

Continuation of the National Emergency With Respect to 

Zimbabwe 

On March 6, 2003, by Executive Order 13288, the President declared a 

national emergency and blocked the property of persons undermining democratic processes or institutions in Zimbabwe, pursuant to the International 

Emergency Economic Powers Act (50 U.S.C. 1701–1706). He took this action 

to deal with the unusual and extraordinary threat to the foreign policy 

of the United States constituted by the actions and policies of certain members of the Government of Zimbabwe and other persons to undermine 

Zimbabwe’s democratic processes or institutions. These actions and policies 

have contributed to the deliberate breakdown in the rule of law in Zimbabwe, 

to politically motivated violence and intimidation in that country, and to 

political and economic instability in the southern African region. 

On November 22, 2005, the President issued Executive Order 13391 to 

take additional steps with respect to the national emergency declared in 

Executive Order 13288 by ordering the blocking of the property of additional 

persons undermining democratic processes or institutions in Zimbabwe. 

On July 25, 2008, the President issued Executive Order 13469, which expanded the scope of the national emergency declared in Executive Order 

13288 and ordered the blocking of the property of additional persons undermining democratic processes or institutions in Zimbabwe. 

Because the actions and policies of these persons continue to pose an 

unusual and extraordinary threat to the foreign policy of the United States, 

the national emergency declared on March 6, 2003, and the measures adopted 

on that date, on November 22, 2005, and on July 25, 2008, to deal with 

that emergency, must continue in effect beyond March 6, 2010. Therefore, 

in accordance with section 202(d) of the National Emergencies Act (50 

U.S.C. 1622(d)), I am continuing for 1 year the national emergency with 

respect to the actions and policies of certain members of the Government 

of Zimbabwe and other persons to undermine Zimbabwe’s democratic processes or institutions. 


pwalker on DSK8KYBLC1PROD with RULES4
10158 Federal Register / Vol. 75, No. 42 / Thursday, March 4, 2010 / Presidential Documents 

This notice shall be published in the Federal Register and transmitted 

to the Congress. 

THE WHITE HOUSE, 

February 26, 2010. [FR Doc. 2010–4805 

Filed 3–3–10; 11:15 am] 

Billing code 3195–W0–P 


pwalker on DSK8KYBLC1PROD with RULES4OB#1.EPS</GPH>
Editorial Note on Part 864
Editorial Note: Nomenclature changes to part 864 appear at 73 FR 35341, June 23, 2008.

§ 864.7320 Fibrinogen/fibrin degradation products assay. ( a ) *Identification.* A fibrinogen/fibrin degradation products assay is a device used to detect and measure fibrinogen degradation products and fibrin degradation products (protein fragments produced by the enzymatic action of plasmin on fibrinogen and fibrin) as an aid in detecting the presence and degree of intravascular coagulation and fibrinolysis (the dissolution of the fibrin in a blood clot) and in monitoring therapy for disseminated intravascular coagulation (nonlocalized clotting in the blood vessels).
( b ) *Classification.* Class II (performance standards).
[45 FR 60615, Sept. 12, 1980]
# C_2015127EN.01000702.xml

| 20.4.2015 | EN | Official Journal of the European Union | C 127/7 |
| --- | --- | --- | --- |

20.4.2015

EN

Official Journal of the European Union

C 127/7

---

Request for a preliminary ruling from the Bundesgerichtshof (Germany) lodged on 22 December 2014 — Simona Kornhaas v Thomas Dithmar as liquidator of the assets of Kornhaas Montage und Dienstleistung Ltd

(Case C-594/14)

(2015/C 127/11)

Language of the case: German

Referring court

Referring court

Bundesgerichtshof

Parties to the main proceedings

Parties to the main proceedings

Applicant: Simona Kornhaas

Applicant:

Defendant: Thomas Dithmar as liquidator of the assets of Kornhaas Montage und Dienstleistung Ltd

Defendant:

Questions referred

Questions referred

| a) | If a liquidator brings an action before a German court against a director of a private company limited by shares under English and Welsh law, in respect of whose assets in Germany insolvency proceedings have been opened pursuant to Article 3(1) of the Insolvency Regulation (1), the purpose of the action being to seek reimbursement of payments which the director made before the opening of the insolvency proceedings but after the company had become unable to pay its debts, is that action governed by German insolvency law within the meaning of Article 4(1) of the Insolvency Regulation? |
| --- | --- |

a)

If a liquidator brings an action before a German court against a director of a private company limited by shares under English and Welsh law, in respect of whose assets in Germany insolvency proceedings have been opened pursuant to Article 3(1) of the Insolvency Regulation (1), the purpose of the action being to seek reimbursement of payments which the director made before the opening of the insolvency proceedings but after the company had become unable to pay its debts, is that action governed by German insolvency law within the meaning of Article 4(1) of the Insolvency Regulation?

private company limited by shares

1

| b) | Does an action as referred to above infringe freedom of establishment under Articles 49 and 54 TFEU? |
| --- | --- |

b)

Does an action as referred to above infringe freedom of establishment under Articles 49 and 54 TFEU?

---

(1)  Council Regulation (EC) No 1346/2000 of 29 May 2000 on insolvency proceedings, OJ 2000 L 160, p. 1.

1

---
Editorial Note on Part 868
Editorial Note: Nomenclature changes to part 868 appear at 73 FR 35341, June 23, 2008.

§ 868.5440 Portable oxygen generator. ( a ) *Identification.* A portable oxygen generator is a device that is intended to release oxygen for respiratory therapy by means of either a chemical reaction or physical means (e.g., a molecular sieve).
( b ) *Classification.* Class II (performance standards).
<TABLE> <S> <C>

<ARTICLE> 5
       
<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-1997
<PERIOD-START>                             JAN-01-1998
<PERIOD-END>                               SEP-30-1998
<CASH>                                         297,498
<SECURITIES>                                         0
<RECEIVABLES>                                   22,417
<ALLOWANCES>                                         0
<INVENTORY>                                     58,860
<CURRENT-ASSETS>                               390,470
<PP&E>                                       6,055,713
<DEPRECIATION>                               3,023,487
<TOTAL-ASSETS>                               3,445,392
<CURRENT-LIABILITIES>                          365,549
<BONDS>                                      2,432,647
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                             0
<OTHER-SE>                                     647,196
<TOTAL-LIABILITY-AND-EQUITY>                 3,445,392
<SALES>                                              0
<TOTAL-REVENUES>                             2,560,091
<CGS>                                                0
<TOTAL-COSTS>                                1,109,165
<OTHER-EXPENSES>                               887,239
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                             167,906
<INCOME-PRETAX>                                395,781
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                            395,781
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                   395,781
<EPS-PRIMARY>                                    97.68
<EPS-DILUTED>                                    97.68
        

</TABLE>